severe aplastic anaemia
Haematology · 2023–2023
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eltrombopag Severe aplastic anaemia (sAA) as first-line treatment in combination with immunosuppressive therapy (horse anti-thymocyte globulin and ciclosporin A), and as… | Nov 2023 | Recommended with restriction | unclear |
What the PBS pays
$27M in government benefit over 2024–25, across 11,807 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| eltrombopag | $27M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| eltrombopagEltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | terminated | 2016-01 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.